Heterologous DNA-prime/protein-boost immunization with a monomeric SARS-CoV-2 spike antigen redundantizes the trimeric receptor-binding domain structure to induce neutralizing antibodies in old mice

A multitude of alterations in the old immune system impair its functional integrity. Closely related, older individuals show, for example, a reduced responsiveness to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines. However, systematic strategies to specifically improve the efficacy of vaccines in the old are missing or limited to simple approaches like increasing the antigen concentration or injection frequencies. We here asked whether the intrinsic, trimeric structure of the SARS-CoV-2 spike (S) antigen and/or a DNA- or protein-based antigen delivery platform affects priming of functional antibody responses particularly in old mice. The used S-antigens were primarily defined by the presence/absence of the membrane-anchoring TM domain and the closely interlinked formation/non-formation of a trimeric structure of the receptor binding domain (S-RBD). Among others, we generated vectors expressing prefusion-stabilized, cell-associated (TM+) trimeric "S2-P" or secreted (TM-) monomeric "S6-PΔTM" antigens. These proteins were produced from vector-transfected HEK-293T cells under mild conditions by Strep-tag purification, revealing that cell-associated but not secreted S proteins tightly bound Hsp73 and Grp78 chaperones. We showed that both, TM-deficient S6-PΔTM and full-length S2-P antigens elicited very similar S-RBD-specific antibody titers and pseudovirus neutralization activities in young (2-3 months) mice through homologous DNA-prime/DNA-boost or protein-prime/protein-boost vaccination. The trimeric S2-P antigen induced high S-RBD-specific antibody responses in old (23-24 months) mice through DNA-prime/DNA-boost vaccination. Unexpectedly, the monomeric S6-PΔTM antigen induced very low S-RBD-specific antibody titers in old mice through homologous DNA-prime/DNA-boost or protein-prime/protein-boost vaccination. However, old mice efficiently elicited an S-RBD-specific antibody response after heterologous DNA-prime/protein-boost immunization with the S6-PΔTM antigen, and antibody titers even reached similar levels and neutralizing activities as in young mice and also cross-reacted with different S-variants of concern. The old immune system thus distinguished between trimeric and monomeric S protein conformations: it remained antigen responsive to the trimeric S2-P antigen, and a simple change in the vaccine delivery regimen was sufficient to unleash its reactivity to the monomeric S6-PΔTM antigen. This clearly shows that both the antigen structure and the delivery platform are crucial to efficiently prime humoral immune responses in old mice and might be relevant for designing "age-adapted" vaccine strategies.

A Systematic Evaluation of the SARS-CoV-2 Vaccine-Induced Anti-S-RBD-Ig Response in a Population of Health Care Workers

In the wake of the COVID-19 pandemic, the novel class of mRNA vaccines has been granted first-time approval for active immunization against SARS-CoV-2 alongside the already established viral vector-based vaccines. In this prospective single-center study, we set out to determine the vaccine-induced humoral immune response in a population of 1512 health care employees after the second and third vaccination, respectively. Anti-SARS-CoV-2 receptor-binding domain (RBD) and nucleocapsid antigen antibody concentrations were assessed using commercially available immunoassays. We could show that, in particular, young study subjects aged below 30 years, as well as those with a prior SARS-CoV-2 infection, developed significantly higher antibody concentrations. Our data further suggest that being in physically close contact with formerly SARS-CoV-2-positive people positively affects the post-vaccination response. Surprisingly, study subjects with a BMI > 30 produced the highest anti-S-RBD Ig antibody levels if they had recently received their third vaccination. Also, heterologous dual vaccine regimens consisting of a BNT162b2 and ChAdOx1 n-CoV-19, a homologous triple combination of BNT162b2, and an application of mRNA-1273 as the third vaccine, were most efficient at eliciting a humoral immune response. Our study substantiates existing evidence, but beyond that, scrutinizes the impact of vaccine agents and their respective combinations, as well as different time intervals on humoral immunogenicity.

BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults

In light of the decreasing immune protection against symptomatic SARS-CoV-2 infection after initial vaccinations and the now dominant immune-evasive Omicron variants, 'booster' vaccinations are regularly performed to restore immune responses. Many individuals have received a primary heterologous prime-boost vaccination with long intervals between vaccinations, but the resulting long-term immunity and the effects of a subsequent 'booster', particularly against Omicron BA.1, have not been defined. We followed a cohort of 23 young adults, who received a primary heterologous ChAdOx1 nCoV-19 BNT162b2 prime-boost vaccination, over a 7-month period and analysed how they responded to a BNT162b2 'booster'. We show that already after the primary heterologous vaccination, neutralization titers against Omicron BA.1 are recognizable but that humoral and cellular immunity wanes over the course of half a year. Residual responsive memory T cells recognized spike epitopes of the early SARS-CoV-2 B.1 strain as well as the Delta and BA.1 variants of concern (VOCs). However, the remaining antibody titers hardly neutralized these VOCs. The 'booster' vaccination was well tolerated and elicited both high antibody titers and increased memory T cell responses against SARS-CoV-2 including BA.1. Strikingly, in this young heterologously vaccinated cohort the neutralizing activity after the 'booster' was almost as potent against BA.1 as against the early B.1 strain. Our results suggest that a 'booster' after heterologous vaccination results in effective immune maturation and potent protection against the Omicron BA.1 variant in young adults.

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants

Background

Heterologous COVID-19 vaccination regimens combining vector- and mRNA-based vaccines are already administered, but data on solicited adverse reactions, immunological responses and elicited protection are limited.

Methods

To evaluate the reactogenicity and humoral as well as cellular immune responses towards most prevalent SARS-CoV-2 variants after a heterologous ChAdOx1 nCoV-19 BNT162b2 prime-boost vaccination, we analysed a cohort of 26 clinic employees aged 25-46 (median 30.5) years who received a ChAdOx1 nCoV-19 prime followed by a BNT162b2 boost after an 8-week interval. Serological data were compared to a cohort which received homologous BNT162b2 vaccination with a 3-week interval (14 individuals aged 25-65, median 42).

Findings

Self-reported solicited symptoms after ChAdOx1 nCoV-19 prime were in line with previous reports and more severe than after the BNT162b2 boost. Antibody titres increased significantly over time resulting in strong neutralization titres two weeks after the BNT162b2 boost and subsequently slightly decreased over the course of 17 weeks. At the latest time point measured, all analysed sera retained neutralizing activity against the currently dominant Delta (B.1.617.2) variant. Two weeks post boost, neutralizing activity against the Alpha (B.1.1.7) and immune-evading Beta (B.1.351) variant was ∼4-fold higher than in individuals receiving homologous BNT162b2 vaccination. No difference was observed in neutralization of Kappa (B.1.617.1). In addition, heterologous vaccination induced CD4⁺ and CD8⁺ T cells reactive to SARS-CoV-2 spike peptides of all analysed variants; Wuhan-Hu-1, Alpha, Beta, Gamma (P.1), and Delta.

Interpretation

In conclusion, heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination is not associated with serious adverse events and induces potent humoral and cellular immune responses. The Alpha, Beta, Delta, and Kappa variants of spike are potently neutralized by sera from all participants and reactive T cells recognize spike peptides of all tested variants. These results suggest that this heterologous vaccination regimen is at least as immunogenic and protective as homologous vaccinations and also offers protection against current variants of concern.

Funding

This project has received funding from the European Union's Horizon 2020 research and innovation programme, the German Research Foundation, the BMBF, the Robert Koch Institute (RKI), the Baden-Württemberg Stiftung, the county of Lower Saxony, the Ministry for Science, Research and the Arts of Baden-Württemberg, Germany, and the National Institutes of Health.

[COVID-19 pandemic-related burden and SARS-CoV-2 prevalence in care facilities]

Hintergrund

Pflegeeinrichtungen sind Belastungen der COVID-19-Pandemie gegenüber besonders exponiert, sowohl in personellen wie strukturellen Bereichen.

Ziel der Arbeit

Prospektive Querschnittsstudie zum punktuellen Infektionsgeschehen, zu psychosozialen Belastungen und zum Umgang der Einrichtungen mit der COVID-19-Pandemie.

Material und Methoden

Systematische Datenerhebung zwischen dem 27.07.2020 und dem 25.08.2020 in 7 Pflegeeinrichtungen in Baden-Württemberg. Dies beinhaltete für Bewohner/Mitarbeiter einen Fragebogen, eine SARS-CoV-2-PCR und Antikörpertestung. Die Einrichtungen wurden auf Umgang und Präventionsmaßnahmen befragt.

Ergebnisse

Von insgesamt 829 SARS-CoV-2-PCR-Tests waren 100 % negativ. 2 Probanden hatten SARS-CoV-2-Antikörper, allerdings ohne positive Anamnese. Keiner der Probanden mit positiver PCR in der Anamnese (n = 6) hatte nachweisbare Antikörper. Mitarbeiter hatten Angst, Mitmenschen, v. a. Heimbewohner, (54,4 %) anzustecken, weniger sich selbst (27,2 %). Als pandemieassoziierte Belastungen wurden in 17,1 % Erschöpfung, 16 % finanzielle Ängste und 13,1 % Schlafstörungen angegeben. Die Bewältigungsstrategien umfassten einen moderaten Anstieg schädlichen Konsumverhaltens (+3,3 % Alkohol, +4,3 % Nikotin). Wesentlich kritischer war dies bei unter 35-Jährigen (+13 % Alkohol, +12,7 % Nikotin). Frauen gaben eine Zunahme des Medikamentengebrauchs um 2,4 % an. 49,8 % der Befragten reduzierten ihre Sozialkontakte, 76,8 % veränderten ihr Hygieneverhalten. Die Einrichtungen waren eingeschränkt auf die COVID-19-Pandemie vorbereitet.

Diskussion

Trotz der niedrigen Punktprävalenz zum Zeitpunkt der Erhebung belastete die COVID-19-Pandemie die Pflegeeinrichtungen in vielfachen Aspekten. Aus den entstandenen Belastungen bei Mitarbeitern müssen Bewältigungs- und Präventionskonzepte resultieren.

Zusatzmaterial online

Zusätzliche Informationen sind in der Online-Version dieses Artikels (10.1007/s00391-021-01931-6) enthalten.

Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing

Highly sensitive and specific platforms for the detection of anti-SARS-CoV-2 antibodies are becoming increasingly important for (1) evaluating potential SARS-CoV-2 convalescent plasma donors, (2) studying the spread of SARS-CoV-2 infections and (3) identifying individuals with seroconversion. This study provides a comparative validation of four anti-SARS-CoV-2 platforms. Unique feature of this study is the use of a representative cohort of COVID-19-convalescent patients with mild-to-moderate disease course. All platforms showed significant correlations with a SARS-CoV-2 plaque-reduction-neutralization test, with highest sensitivities for the Euroimmun and the Roche platforms, suggesting their preferential use for screening of persons at increased risk of SARS-CoV-2 infections.

Effect of temperature on the phenology of Chilo partellus (Swinhoe) (Lepidoptera, Crambidae); simulation and visualization of the potential future distribution of C. partellus in Africa under warmer temperatures through the development of life-table parameters

Maize (Zea mays) is a major staple food in Africa. However, maize production is severely reduced by damage caused by feeding lepidopteran pests. In East and Southern Africa, Chilo partellus is one of the most damaging cereal stem borers mainly found in the warmer lowland areas. In this study, it was hypothesized that the future distribution and abundance of C. partellus may be affected greatly by the current global warming. The temperature-dependent population growth potential of C. partellus was studied on artificial diet under laboratory conditions at six constant temperatures (15, 18, 20, 25, 28, 30, 32 and 35 °C), relative humidity of 75±5% and a photoperiod of L12:L12 h. Several non-linear models were fitted to the data to model development time, mortality and reproduction of the insect species. Cohort updating algorithm and rate summation approach were stochastically used for simulating age and stage structure populations and generate life-table parameters. For spatial analysis of the pest risk, three generic risk indices (index of establishment, generation number and activity index) were visualized in the geographical information system component of the advanced Insect Life Cycle modeling (ILCYM) software. To predict the future distribution of C. partellus we used the climate change scenario A1B obtained from WorldClim and CCAFS databases. The maps were compared with available data on the current distribution of C. partellus in Kenya. The results show that the development times of the different stages decreased with increasing temperatures ranging from 18 to 35 °C; at the extreme temperatures, 15 and 38 °C, no egg could hatch and no larvae completed development. The study concludes that C. partellus may potentially expands its range into higher altitude areas, highland tropics and moist transitional regions, with the highest maize potential where the species has not been recorded yet. This has serious implication in terms of food security since these areas produce approximately 80% of the total maize in East Africa.